CurrentEndo coverage · page 55 of 55

Diabetes, Obesity and Metabolism

Briefs 2,161–2,200 of 2,200 CurrentEndo has covered from this journal, newest publication first

Latest from Diabetes, Obesity and Metabolism

All coverage, newest first

Diabetes Obes Metab2 Nov 2022
Ethnic and socioeconomic disparities in initiation of second‐line antidiabetic treatment for people with type 2 diabetes in England: A cross‐sectional study
Cross-sectional studyT2D & other
Diabetes Obes Metab2 Nov 2022
Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon‐like peptide‐1 receptor agonist use
Randomized controlled trialT2D & other
Diabetes Obes Metab2 Nov 2022
Non‐alcoholic fatty liver disease and complications in type 1 and type 2 diabetes: A Mendelian randomization study
Research articleComplications
Diabetes Obes Metab2 Nov 2022
Once‐weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK : A long‐term cost‐effectiveness analysis based on SUSTAIN 11
Research articleT2D & other
Diabetes Obes Metab2 Nov 2022
Sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes: Are clinical trial benefits for heart failure reflected in real‐world clinical practice? A systematic review and meta‐analysis of observational studies
Meta-analysisT2D & other
Diabetes Obes Metab2 Nov 2022
The impact of family history of type 2 diabetes on clinical heterogeneity in idiopathic type 1 diabetes
Cross-sectional studyT1D
Diabetes Obes Metab2 Nov 2022
Weight regain after behavioural weight management programmes and its impact on quality of life and cost effectiveness: Evidence synthesis and health economic analyses
Meta-analysisObesity
Diabetes Obes Metab28 Oct 2022
Effect of faecal microbial transplant via colonoscopy in patients with severe obesity and insulin resistance: A randomized double‐blind, placebo‐controlled Phase 2 trial
Randomized controlled trialObesity
Diabetes Obes Metab28 Oct 2022
Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses
Secondary analysisObesity
Diabetes Obes Metab24 Oct 2022
Cardiovascular risk and lifetime benefit from preventive treatment in type 2 diabetes: A post hoc analysis of the CAPTURE study
Secondary analysisT2D & other
Diabetes Obes Metab24 Oct 2022
Effects of glucose‐lowering agents on cardiovascular and renal outcomes in subjects with type 2 diabetes: An updated meta‐analysis of randomized controlled trials with external adjudication of events
Meta-analysisT2D & other
Diabetes Obes Metab24 Oct 2022
Factors associated with successful weight loss after liraglutide treatment for obesity
Secondary analysisObesity
Diabetes Obes Metab24 Oct 2022
Impact of iron supplementation on gestational diabetes mellitus: A literature review
Research articleDiabetes in pregnancy
Diabetes Obes Metab23 Oct 2022
A 96‐week, double‐blind, randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adults
Randomized controlled trialT2D & other
Diabetes Obes Metab23 Oct 2022
Canagliflozin reduces proteinuria by targeting hyperinsulinaemia in diabetes patients with heart failure: A post hoc analysis of the CANDLE trial
Secondary analysisT2D & other
Diabetes Obes Metab23 Oct 2022
Cost‐utility analysis of semaglutide for type 2 diabetes after its addition to the National Medical Insurance System in China
Research articleT2D & other
Diabetes Obes Metab14 Oct 2022
Rationale and design of the phase 3a development programme ( ONWARDS 1–6 trials) investigating once‐weekly insulin icodec in diabetes
Trial designT2D & other
Diabetes Obes Metab14 Oct 2022
Saxagliptin combined with additional oral antihyperglycaemic agents in drug‐naive diabetic patients with high glycosylated haemoglobin: A 24‐week, multicentre, randomized, open‐label, active parallel‐controlled group clinical trial in China ( SUCCESS )
Randomized controlled trialT2D & other
Diabetes Obes Metab10 Oct 2022
Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase‐4 inhibitors: Real world evidence from the Nordic EMPRISE study
Cohort studyT2D & other
Diabetes Obes Metab9 Oct 2022
Real‐world effectiveness and safety of insulin glargine 300 U/ml in insulin‐naïve people with type 2 diabetes in the Latin America region: A subgroup analysis of the ATOS
Secondary analysisT2D & other
Diabetes Obes Metab4 Oct 2022
Mendelian randomization identifies age at menarche as an independent causal effect factor for gestational diabetes mellitus
Research articleDiabetes in pregnancy
Diabetes Obes Metab29 Sep 2022
External validation and extension of the TIMI risk score for heart failure in diabetes for patients with recent acute coronary syndrome: An analysis of the EXAMINE trial
Secondary analysisT2D & other
Diabetes Obes Metab28 Sep 2022
Cross‐sectional association of metrics derived from continuous glucose monitoring with cognitive performance in older adults with type 2 diabetes
Cross-sectional studyTechnology
Diabetes Obes Metab27 Sep 2022
Epicardial adipose tissue thickness is associated with reduced peak oxygen consumption and systolic reserve in patients with type 2 diabetes and normal heart function
Cross-sectional studyT2D & other
Diabetes Obes Metab27 Sep 2022
Incident heart failure, arrhythmias and cardiovascular outcomes with sodium‐glucose cotransporter 2 ( SGLT2 ) inhibitor use in patients with diabetes: Insights from a global federated electronic medical record database
Cohort studyT2D & other
Diabetes Obes Metab27 Sep 2022
Mechanisms underlying the blood pressure‐lowering effects of empagliflozin, losartan and their combination in people with type 2 diabetes: A secondary analysis of a randomized crossover trial
Secondary analysisT2D & other
Diabetes Obes Metab26 Sep 2022
All‐cause and cardiorenal mortality in 6 million adults with and without type 2 diabetes: A comparative, trend analysis in Canada, Spain, and the UK
Cohort studyT2D & other
Diabetes Obes Metab26 Sep 2022
Clinical significance of prediabetes, undiagnosed diabetes and diagnosed diabetes on critical outcomes in COVID‐19: Integrative analysis from the Japan COVID ‐19 task force
Cohort studyT2D & other
Diabetes Obes Metab26 Sep 2022
Real‐world usage of sulphonylureas in Asian patients with type 2 diabetes using the Joint Asia Diabetes Evaluation ( JADE ) register
Cross-sectional studyT2D & other
Diabetes Obes Metab23 Sep 2022
Efficacy of intermittent short‐term use of a real‐time continuous glucose monitoring system in non‐insulin–treated patients with type 2 diabetes: A randomized controlled trial
Randomized controlled trialTechnology
Diabetes Obes Metab23 Sep 2022
Larger effect size in composite kidney outcomes than in major cardiovascular events associated with sodium‐glucose cotransporter‐2 ( SGLT2) inhibitors compared with glucagon‐like peptide‐1 receptor agonists ( GLP ‐1 RAs) : A pooled analysis of type 2 diabetes trials
Meta-analysisT2D & other
Diabetes Obes Metab21 Sep 2022
Metabolic profile‐based subgroups can identify differences in brain volumes and brain iron deposition
Cross-sectional study
Diabetes Obes Metab21 Sep 2022
Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the FIGHT trial
Secondary analysis
Diabetes Obes Metab20 Sep 2022
Sodium‐glucose cotransporter‐2 inhibitors and the risk of gout in patients with type 2 diabetes mellitus: A propensity‐score‐matched, new‐user design study with an active comparator using the IQVIA Medical Research Data UK database
Cohort studyT2D & other
Diabetes Obes Metab19 Sep 2022
iGlarLixi versus basal plus Rapid‐Acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify Real‐World study
Cohort studyT2D & other
Diabetes Obes Metab16 Sep 2022
Treatment patterns and glycated haemoglobin levels over 36 months in individuals with type 2 diabetes initiating second‐line glucose‐lowering therapy: The global DISCOVER study
Cohort studyT2D & other
Diabetes Obes Metab12 Sep 2022
A randomized, double‐blind, crossover study of the effect of the fluoroquinolone moxifloxacin on glucose levels and insulin sensitivity in young men and women
Randomized controlled trial
Diabetes Obes Metab12 Sep 2022
Associations of microvascular complications with all‐cause death in patients with diabetes and COVID ‐19: The CORONADO , ABCD COVID‐19 UK national audit and AMERICADO study groups
Meta-analysisComplications
Diabetes Obes Metab8 Sep 2022
Efficacy and safety of ultra‐rapid lispro versus lispro in children and adolescents with type 1 diabetes: The PRONTO‐Peds trial
Randomized controlled trialT1D
Diabetes Obes Metab4 Sep 2022
Global mortality of diabetic foot ulcer: A systematic review and meta‐analysis of observational studies
Meta-analysisComplications

All 2,200 Briefs in ExploreShowing Briefs 2,161–2,200 of 2,200, newest first